{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:12:36Z","timestamp":1778055156023,"version":"3.51.4"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12894-017-0281-8","type":"journal-article","created":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T06:46:29Z","timestamp":1507099589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4915-7546","authenticated-orcid":false,"given":"Tobias","family":"Nordstr\u00f6m","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Adolfsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Gr\u00f6nberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Eklund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,3]]},"reference":[{"key":"281_CR1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.urology.2016.07.001","volume":"96","author":"ED Crawford","year":"2016","unstructured":"Crawford ED, Rosenberg MT, Partin AW, Cooperberg MR, Maccini M, Loeb S, et al. An approach using PSA levels of 1.5\u2009ng\/mL as the cutoff for prostate cancer screening in primary care. Urology. 2016;96:116\u201320.","journal-title":"Urology"},{"key":"281_CR2","doi-asserted-by":"crossref","unstructured":"Vickers AJ, Cronin AM, Bjork T, Manjer J, Nilsson PM, Dahlin A, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ. 2010 ed. 2010;341:c4521.","DOI":"10.1136\/bmj.c4521"},{"key":"281_CR3","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/S1470-2045(15)00361-7","volume":"16","author":"H Gr\u00f6nberg","year":"2015","unstructured":"Gr\u00f6nberg H, Adolfsson J, Aly M, Nordstr\u00f6m T, Wiklund P, Brandberg Y, et al. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol. 2015;16:1667\u201376.","journal-title":"Lancet Oncol"},{"key":"281_CR4","unstructured":"Eklund M, Nordstr\u00f6m T, Aly M, Adolfsson J, Wiklund P, Brandberg Y, et al. The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50\u201369 yr Compared with Current Prostate Cancer Testing. European Urology Focus [Internet]. 2016. Available from: http:\/\/www.eu-focus.europeanurology.com\/article\/S2405-4569(16)30156-0\/fulltext ."},{"key":"281_CR5","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","volume":"384","author":"FH Schr\u00f6der","year":"2014","unstructured":"Schr\u00f6der FH, Hugosson J, Roobol MJ, Tammela TLJ, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European randomised study of screening for prostate cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384:2027\u201335.","journal-title":"Lancet"},{"key":"281_CR6","doi-asserted-by":"crossref","unstructured":"Nordstr\u00f6m T, Gr\u00f6nberg H, Adolfsson J, Aly M, Eklund M. Balancing Overdiagnosis and early detection of prostate cancer using the Stockholm-3 model. European Urology Focus. 2016;","DOI":"10.1016\/j.euf.2016.11.016"},{"key":"281_CR7","doi-asserted-by":"crossref","unstructured":"Nordstr\u00f6m T, Gr\u00f6nberg H, Adolfsson J, Aly M, Eklund M. Balancing Overdiagnosis and Early Detection of Prostate Cancer using the Stockholm-3 Model. Catto J, editor. European Urology Focus. 2016.","DOI":"10.1016\/j.euf.2017.01.014"},{"key":"281_CR8","unstructured":"Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level. N. Engl. J. Med. 2004 ed. 2004;350:2239\u201346."}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-017-0281-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T22:26:57Z","timestamp":1659565617000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-017-0281-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,3]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["281"],"URL":"https:\/\/doi.org\/10.1186\/s12894-017-0281-8","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,3]]},"article-number":"92"}}